Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Garland

Showing results (771-780 of 803) with videos related to

Pageof 81
Sort By:
Plos One|November 22, 2013
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA studyUnnop Jaisamrarn, Xavier Castellsagué, Suzanne M Garland, et al.
Lancet (London, England)|September 10, 2017
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trialWarner K Huh, Elmar A Joura, Anna R Giuliano, et al.
The Lancet. Oncology|November 15, 2011
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialMatti Lehtinen, Jorma Paavonen, Cosette M Wheeler, et al.
Obstetrics and Gynecology|July 12, 2018
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of AgeSuzanne M Garland, Elmar A Joura, Kevin A Ault, et al.
The Lancet. Global Health|March 14, 2024
Point-of-care testing and treatment of sexually transmitted and genital infections to improve birth outcomes in high-burden, low-resource settings (WANTAIM): a pragmatic cluster randomised crossover trial in Papua New GuineaMichaela A Riddell, Lisa M Vallely, Alice Mengi, et al.
The Journal of Infectious Diseases|August 13, 2018
HLA and KIR Associations of Cervical NeoplasiaXiao Bao, Aimee L Hanson, Margaret M Madeleine, et al.
Journal of Virology|April 1, 2016
Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome SequencesMateja M Jelen, Zigui Chen, Boštjan J Kocjan, et al.
The Journal of Infectious Diseases|May 17, 2018
Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian CountriesS M Garland, P Pitisuttithum, H Y S Ngan, et al.
BMJ (Clinical Research Ed.)|February 12, 2020
Short term association between ozone and mortality: global two stage time series study in 406 locations in 20 countriesAna M Vicedo-Cabrera, Francesco Sera, Cong Liu, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
Pageof 81

Showing results (771-780 of 803) with videos related to

Sort By:
Pageof 81
Plos One|November 22, 2013
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA studyUnnop Jaisamrarn, Xavier Castellsagué, Suzanne M Garland, et al.
Lancet (London, England)|September 10, 2017
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trialWarner K Huh, Elmar A Joura, Anna R Giuliano, et al.
The Lancet. Oncology|November 15, 2011
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialMatti Lehtinen, Jorma Paavonen, Cosette M Wheeler, et al.
Obstetrics and Gynecology|July 12, 2018
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of AgeSuzanne M Garland, Elmar A Joura, Kevin A Ault, et al.
The Lancet. Global Health|March 14, 2024
Point-of-care testing and treatment of sexually transmitted and genital infections to improve birth outcomes in high-burden, low-resource settings (WANTAIM): a pragmatic cluster randomised crossover trial in Papua New GuineaMichaela A Riddell, Lisa M Vallely, Alice Mengi, et al.
The Journal of Infectious Diseases|August 13, 2018
HLA and KIR Associations of Cervical NeoplasiaXiao Bao, Aimee L Hanson, Margaret M Madeleine, et al.
Journal of Virology|April 1, 2016
Global Genomic Diversity of Human Papillomavirus 11 Based on 433 Isolates and 78 Complete Genome SequencesMateja M Jelen, Zigui Chen, Boštjan J Kocjan, et al.
The Journal of Infectious Diseases|May 17, 2018
Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian CountriesS M Garland, P Pitisuttithum, H Y S Ngan, et al.
BMJ (Clinical Research Ed.)|February 12, 2020
Short term association between ozone and mortality: global two stage time series study in 406 locations in 20 countriesAna M Vicedo-Cabrera, Francesco Sera, Cong Liu, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.
Pageof 81